Mô tả

Primary efficacy endpoints including the number and duration of allergic rhinitis exacerbations are compared between Lertal and control groups during the pollen season.

Figure 3

Chart

Source Paper

A polycentric, randomized, parallel-group, study on Lertal®, a multicomponent nutraceutical, as preventive treatment in children with allergic rhinoconjunctivitis: phase II.

Italian journal of pediatrics (2019)

PMID: 31319883

DOI: 10.1186/s13052-019-0678-y

Cite This Figure

![Figure 3: Primary efficacy endpoints including the number and duration of allergic rhinitis exacerbations are compared between Lertal and control groups during the pollen season.]()

> Source: Gianluigi Marseglia et al. "A polycentric, randomized, parallel-group, study on Lertal®, a multicomponent nu." *Italian journal of pediatrics*, 2019. PMID: [31319883](https://pubmed.ncbi.nlm.nih.gov/31319883/)

<figure>
  <img src="" alt="Primary efficacy endpoints including the number and duration of allergic rhinitis exacerbations are compared between Lertal and control groups during the pollen season." />
  <figcaption>Figure 3. Primary efficacy endpoints including the number and duration of allergic rhinitis exacerbations are compared between Lertal and control groups during the pollen season.<br>  Source: Gianluigi Marseglia et al. "A polycentric, randomized, parallel-group, study on Lertal®, a multicomponent nu." <em>Italian journal of pediatrics</em>, 2019. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31319883/">31319883</a></figcaption>
</figure>

Bằng chứng liên quan

Quercetin cho Allergic Rhinitis

Xếp hạng C · 5 nghiên cứu